OA11.04 Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial
2021; Elsevier BV; Volume: 16; Issue: 3 Linguagem: Inglês
10.1016/j.jtho.2021.01.314
ISSN1556-1380
AutoresSantiago Ponce-Aix, Gregory M. Coté, Alejandro Falcón, E. Jimenez-Aguilar, W. Marston Linehan, Ioan Şimon, M.J. Flor, Ramiro Manzano-Núñez, Antonio Moreno Jiménez, Elisabeth Jiménez, S. Extremera, Carmen Kahatt, Ali Zeaiter, Luis Paz‐Ares,
Tópico(s)Lung Cancer Treatments and Mutations
ResumoLurbinectedin is a novel anti-cancer agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of the tumor microenvironment. In June 2020, the US FDA granted accelerated approval to lurbinectedin (ZepzelcaTM) for the treatment of adult patients (pts) with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy based on the results of a phase II study (Trigo et al. Lancet Oncol 2020). Preclinical evidence of synergism was observed for lurbinectedin in combination with irinotecan.
Referência(s)